The study of sleep-disordered breathing at high altitude for evaluating and treatment

The study of sleep-disordered breathing at high altitude for evaluating and treatment - SDBHA study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015581

Enrollment

Registered

2014-11-01

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sleep-disordered breathing

Interventions

To apply continuous positive airway pressure (CPAP) and acetazolamide p.o. for the eligible SDB patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects who will stay at high altitude 2. Suspected SDB patients who have 3% oxygen desaturation index (ODI3%) with over 5/h and less than 15/h

Exclusion criteria

Exclusion criteria: Unstable ishchemic heart disease Pulmonary hypertension History of strokes Heart failure Resiratory failure Renal failure Neuropsychologic disease History of upper airway surgery Treated with drugs affecting respiration and sleep( acetazolamide, benzodiazepines, narcotics subjects who are judged unsuitable by doctors

Design outcomes

Primary

Measure	Time frame
Apnea-hypopnea index(AHI)	—

Secondary

Measure	Time frame
Oxygen saturation (Time below 90% , or minimum) Sleep quality Complications	—

Countries

Japan

Contacts

Public ContactHideaki Nakayama

Tokyo Medical University Department of Respiratory Medicine

hidenaka@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026